AstraZeneca and Daiichi Sankyo are changing the approval submission strategy for its planned Enhertu successor, datopotamab deruxtecan (Dato-DXd), after a few missed trials.
The companies voluntarily withdrew their filing in nonsquamous non-small cell lung cancer ...
↧
